Humacyte reports a GAAP loss of $0.16 per share and $0.41 million revenue, missing estimates by $0.7 million.
Humacyte (HUMA) shares declined 15% after the company posted a wider-than-expected second-quarter loss and revenue below analyst forecasts. The biotech firm reported a GAAP loss per share of $0.16, missing consensus by 6 cents.
Revenue for the quarter totaled $0.41 million, falling $0.7 million short of expectations. The results highlight ongoing challenges in meeting financial targets amid operational costs.
The stock drop reflects investor disappointment over the earnings miss and revenue shortfall.